Literature DB >> 23900829

European drugs agency clashes with scientists over safety of GLP-1 drugs.

Deborah Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23900829     DOI: 10.1136/bmj.f4838

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Neural control of energy balance: translating circuits to therapies.

Authors:  Laurent Gautron; Joel K Elmquist; Kevin W Williams
Journal:  Cell       Date:  2015-03-26       Impact factor: 41.582

2.  Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!

Authors:  Michael A Nauck; Juris J Meier
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

3.  Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.

Authors:  Jean-Luc Faillie; Laurent Azoulay; Valerie Patenaude; Dominique Hillaire-Buys; Samy Suissa
Journal:  BMJ       Date:  2014-04-24

Review 4.  The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.

Authors:  Konstantinos Makrilakis
Journal:  Int J Environ Res Public Health       Date:  2019-07-30       Impact factor: 3.390

Review 5.  Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.

Authors:  Ling Li; Jiantong Shen; Malgorzata M Bala; Jason W Busse; Shanil Ebrahim; Per Olav Vandvik; Lorena P Rios; German Malaga; Evelyn Wong; Zahra Sohani; Gordon H Guyatt; Xin Sun
Journal:  BMJ       Date:  2014-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.